Merck To Acquire Tilos Therapeutics for ~ $773M

Shots:

• Merck acquires Tilos Therapeutics, in all-stock transaction. Tilos Therapeutics to receive upfront and contingent milestone payments, making the total deal value ~$773M
• The focus of the acquisition is to strengthen Merck’s footprint with the addition of Tilos’ antibodies modulating TGFβ portfolio targeting cancer, fibrosis and autoimmune diseases
• TGFβ is a cytokine secreted as a complex with the protein, latency-associated peptide (LAP). Tilos Therapeutics was founded by the collaboration of BI Venture Fund and Partners Innovation Fund

Click here to read full press release/ article | Ref: Merck | Image: Livemint